Ligand Pharmaceuticals (LGND) Change in Receivables (2010 - 2026)
Ligand Pharmaceuticals (LGND) posted Change in Receivables of -$6.4 million for Q1 2026, down 407.09% sequentially from $2.1 million in Q4 2025, and down 1212.67% YoY from $576000.0 in Q1 2025.
Ligand Pharmaceuticals (LGND) Change in Receivables (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported Change in Receivables for 17 years, with the latest figure at -$6.4 million in Q1 2026.
- Quarterly Change in Receivables fell 1212.67% year-over-year to -$6.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.8 million (up 40.54% YoY) and the FY2025 annual result came in at $21.7 million, up 236.54% from the prior year.
- Change in Receivables retreated to -$6.4 million in Q1 2026 per LGND's latest filing, from $2.1 million in the prior quarter.
- Over five years, Change in Receivables peaked at $20.4 million in Q2 2022 and troughed at -$43.6 million in Q1 2022.
- A 5-year average of -$1.8 million and a median of $576000.0 in 2025 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2022 and 2024: Change in Receivables plunged 1709.95% in 2022, then surged 757.15% in 2024.
- Over 5 years, Change in Receivables stood at -$34.8 million in 2022, then soared by 91.85% to -$2.8 million in 2023, then soared by 299.82% to $5.7 million in 2024, then tumbled by 63.16% to $2.1 million in 2025, then plunged by 407.09% to -$6.4 million in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered -$6.4 million, $2.1 million, and $16.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | 13.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.85 Mn |
| Jun 30, 2026 | 13.85 Mn |
| Mar 31, 2026 | -6.41 Mn |
| Mar 31, 2026 | -6.41 Mn |
| Dec 31, 2025 | 2.09 Mn |
| Dec 31, 2025 | 2.09 Mn |
| Sep 30, 2025 | 16.31 Mn |
| Sep 30, 2025 | 16.31 Mn |
| Jun 30, 2025 | 2.77 Mn |
| Jun 30, 2025 | 2.77 Mn |
| Mar 31, 2025 | 576,000.00 |
| Mar 31, 2025 | 576,000.00 |
| Dec 31, 2024 | 5.67 Mn |
| Dec 31, 2024 | 5.67 Mn |
| Sep 30, 2024 | -4.79 Mn |
| Sep 30, 2024 | -4.79 Mn |
| Jun 30, 2024 | 9.05 Mn |
| Jun 30, 2024 | 9.05 Mn |
| Mar 31, 2024 | -3.46 Mn |
| Mar 31, 2024 | -3.46 Mn |